New cancer pill tested in patients with no other options
NCT ID NCT00463814
First seen Nov 13, 2025 · Last updated May 07, 2026 · Updated 16 times
Summary
This early-phase study tested a new oral drug called AZD6244 in 58 adults with advanced solid tumors that had stopped responding to standard therapies. The main goal was to check the drug's safety and how the body processes it. Researchers monitored side effects, vital signs, and lab results to determine if the drug is tolerable enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Nijmegen, 6525 GA, Netherlands
-
Research Site
Utrecht, 3584 CX, Netherlands
-
Research Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.